Ticker
PFE

Price
43.76
Stock movement down
-0.30 (-0.68%)
Company name
Pfizer Inc
Exchange
(NYSE
,
Currency
USD
)
Sector
Healthcare >
Drug Manufacturers-General
Market cap
245.64B
Ent value
346.80B
Price/Sales
2.46
Price/Book
2.64
Div yield
3.75%
Div growth
5.70%
Growth years
11
FCF payout
51.09%
Trailing P/E
8.25
Forward P/E
8.99
PEG
1.54
EPS growth
14.70%
1 year return
-18.02%
3 year return
6.57%
5 year return
4.76%
10 year return
5.27%
Last updated: 2023-02-06

BUSINESS INSIGHT

Segment Revenues ($M)

Loading...
Covid-19 vaccine comments

BNT162b2, which was granted an emergency use authorization (EUA) in the U.S. in December 2020, and which contributed $154 million in sales in the fourth quarter

Geographic Revenues ($M)

Loading...

DIVIDENDS

Dividend yield - 5y

Loading...
Dividend yield data
Dividend per share1.64
Dividend yield3.75%
Payout frequencyQuarterly
Maximum yield5.34%
Average yield3.68%
Minimum yield2.61%
Discount to avg yield1.85%
Upside potential1.89%
Yield as % of max yield70.24%

Yield distribution (inverse percentile) - 5y

Loading...
Yield distribution data
Dividend yield3.75%
Current yield distribution44.60%
Yield at 100% (Min)2.61%
Yield at 90%3.11%
Yield at 80%3.25%
Yield at 50% (Median)3.69%
Yield at 20%4.07%
Yield at 10%4.26%
Yield at 0% (Max)5.34%

Dividend per share

Loading...
Dividend per share data
Years of growth11 years
CCC statusDividend Contender
Dividend per share1.64
Payout frequencyQuarterly
Ex-div date26 Jan 2023
EPS (TTM)5.21
EPS (1y forward)4.87
EPS growth (5y)14.70%
EPS growth (5y forward)5.37%

Dividend growth

Loading...
Please create a free account or log in to access this chart
Dividend growth data
PFES&P500
DGR MR2.50%11.59%
DGR TTM2.55%10.54%
DGR 3 years5.46%4.00%
DGR 5 years5.70%5.65%
DGR 10 years6.74%7.37%
DGR 15 years2.54%5.83%
Time since last change announced61 days
EPS growth (5y)14.70%
EPS growth (5y forward)5.37%

Payout ratio

Loading...
Please create a free account or log in to access this chart
Payout ratio data
EPS coverageFCF coverage
TTM29.99%51.09%
Average--
Forward33.68%-

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E8.25
Price to OCF9.23
Price to FCF14.06
Price to EBITDA8.55
EV to EBITDA12.07

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales2.46
Price to Book2.64
EV to Sales3.48

FINANCIALS

Per share

Loading...
Per share data
Current share count5.61B
EPS (TTM)5.21
FCF per share (TTM)3.06

Income statement

Loading...
Income statement data
Revenue (TTM)99.68B
Gross profit (TTM)65.39B
Operating income (TTM)35.16B
Net income (TTM)29.77B
EPS (TTM)5.21
EPS (1y forward)4.87

Margins

Loading...
Margins data
Gross margin (TTM)65.60%
Operating margin (TTM)35.27%
Profit margin (TTM)29.87%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash1.30B
Net receivables18.62B
Total current assets70.40B
Goodwill49.44B
Intangible assets28.15B
Property, plant and equipment0.00
Total assets195.35B
Accounts payable6.27B
Short/Current long term debt35.68B
Total current liabilities44.31B
Total liabilities102.46B
Shareholder's equity92.89B
Net tangible assets8.25B

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)26.60B
Capital expenditures (TTM)3.23B
Free cash flow (TTM)17.47B
Dividends paid (TTM)8.93B

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity32.05%
Return on Assets15.24%
Return on Invested Capital22.98%
Cash Return on Invested Capital13.49%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open44.19
Daily high44.30
Daily low43.73
Daily Volume18.1M
All-time high61.25
1y analyst estimate55.49
Beta0.63
EPS (TTM)5.21
Dividend per share1.64
Ex-div date26 Jan 2023
Next earnings date1 May 2023

Downside potential

Loading...
Downside potential data
PFES&P500
Current price drop from All-time high-28.56%-14.21%
Highest price drop-76.70%-56.47%
Date of highest drop2 Mar 20099 Mar 2009
Avg drop from high-29.90%-11.49%
Avg time to new high35 days13 days
Max time to new high5620 days1805 days
COMPANY DETAILS
PFE (Pfizer Inc) company logo
Marketcap
245.64B
Marketcap category
Large-cap
Description
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Employees
79000
SEC filings
CEO
Albert Bourla
Country
USA
City
New York
Stock type
Common stock
CCC status
Dividend Contender
Dividend Frequency
Quarterly
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Last year was a stellar one for Pfizer (NYSE: PFE). In January, Pfizer announced not only its latest earnings results but also a forecast for 2023, which tells investors what they already knew was in...
February 7, 2023
Musk ‘saved Twitter from bankruptcy,’ Biden and the China balloon saga, Pfizer tackles waning Covid-19 drug demand, and other news to start your day.
February 6, 2023
January gave investors hope that the bear market is finally ending. The S&P 500 rose 6%, while the tech-heavy Nasdaq jumped more than 10%. A handful of important market trends emerged thanks to evol...
February 6, 2023
Pharmaceutical companies that made billions from the pandemic over the past two years selling vaccines and treatments are now up against a steep COVID cliff and investor pressure to spend their wind...
February 6, 2023
Pharmaceutical companies that made billions from the pandemic over the past two years selling vaccines and treatments are now up against a steep COVID cliff and investor pressure to spend their wind...
February 6, 2023
With its packed pipeline, growing R&D spending, and potential deals and share buybacks, there's more to the drugmaker than the market realizes.
February 5, 2023
In this article, we take a look at 12 safe stocks to buy for the long-term according to hedge funds. You can skip our detailed analysis of safe stocks and go directly to read 5 Safe Stocks to Buy Acco...
February 5, 2023
The two companies, known for their vaccines, could see their businesses benefit from a yearly COVID-19 shot.
February 4, 2023
In this article, we discuss the 10 hot healthcare stocks to buy now. If you want to read about some more hot healthcare stocks to buy now, go directly to 5 Hot Healthcare Stocks To Buy Now. The rise o...
February 3, 2023
CanSino Biologics Chief Executive Yu Xuefeng said on Friday he was confident his company's experimental COVID-19 vaccine using messenger RNA (mRNA) technology was as good as shots from Moderna and Pf...
February 3, 2023
Next page